Outcome of Neonatal Hyperbilirubinemia from a Tertiary Care Hospital in Eastern Nepal: A Cross-sectional Study

• Shyam Prasad Kafle¹ • Mukesh Bhatta¹ • Ramesh Shrestha² • Sarita Situala³ • Namu Koirala³ • Anupam Koirala⁴

Submitted 13 December 2020
Accepted 12 March 2021
Published 30 June 2021

Abstract

Background: Timely detection and treatment of pathological hyperbilirubinemia in newborns can prevent acute bilirubin encephalopathy and its consequences. We aimed to identify its occurrence, presentation time, phototherapy duration, need for exchange transfusion, and outcome.

Methods: In this cross-sectional study, we enrolled all the babies admitted for pathological neonatal hyperbilirubinemia in the university hospital of BPKIHS in a one-year duration. Babies with life-threatening congenital malformations or conjugated bilirubin > 20% of total serum bilirubin or > 2 mg/dl were excluded. Obstetric profile of mothers, clinical and laboratory parameters of babies, onset time of pathological jaundice, duration of phototherapy, need for exchange transfusion or intravenous immunoglobulin were recorded. Neonatal outcome was classified as good and poor and its association with potential predictors analyzed.

Results: One-hundred and fifty babies developed neonatal jaundice requiring treatment. The most common causes included ABO and Rh setting. No cause was found in 26 (18%) babies. One-hundred and eight babies (72%) were only managed with phototherapy whereas 42 (28%) required both phototherapy and double volume exchange therapy. The majority (84.5%) had good outcome without any residual neurological deficit at discharge. Babies with total serum bilirubin > 20 mg/dl at presentation, duration of phototherapy > 44.8 h, ABO setting, hemolysis, and out born status significantly developed poor outcome (p < 0.05).

Conclusion: About 15% of the babies with hyperbilirubinemia had acute bilirubin encephalopathy at discharge suggestive of poor outcome. Babies with high bilirubin at presentation, longer duration of phototherapy, ABO settings, hemolysis, and out born status developed poor outcome.

Keywords: Bilirubin, Hyperbilirubinemia, Nepal, Newborn
Neonatal jaundice is reported in > 50% of newborns [1, 2]. The most common form of neonatal jaundice is physiological but sometimes serum bilirubin levels exceed the normal range to become pathological [3, 4]. Timely detection of pathological hyperbilirubinemia and prompt treatment can prevent severe consequences like bilirubin encephalopathy. Apart from phototherapy, severe hyperbilirubinemia is managed with exchange transfusion which may be associated with complications. With the advent of newer phototherapy techniques, better understanding of pathophysiology, underlying causes, and interventions, the need for exchange transfusion is decreasing. We conducted this study to analyze the average time of presentation, possible causes, mean duration of phototherapy, need for exchange transfusion and discharge outcome of pathological jaundice in newborns.

**METHODS**

This cross-sectional study was conducted in B. P. Koirala Institute of Health Sciences (BPKIHS), Dharan from August 2015 to July 2016. Ethical clearance was taken from the Institutional Review Committee and informed consent was taken from the parents before enrollment in the study. All the babies admitted in the neonatal ward, nursery, neonatal intensive care unit (NICU) and pediatric wards diagnosed with neonatal hyperbilirubinemia requiring treatment were enrolled. Babies with life-threatening congenital malformations or those having conjugated serum bilirubin > 20% of total serum bilirubin or > 2 mg/dl were excluded.

Serum bilirubin was measured by Jendrassik and Grof method by a fully automated analyzer [5]. A pre-designed proforma was filled from the case files; details such as demographic and obstetric profile of the mother, physical examination of the baby, time since birth to the appearance of pathological jaundice, other relevant blood investigations, duration of phototherapy, need for exchange transfusion, intravenous immunoglobulin, and intravenous fluid requirement were recorded sequentially and serially. Babies were classified into term, preterm, late preterm, appropriate for gestational age, low birth weight, small for gestational age as per the standard definitions [6].

All babies who had neither Rh nor ABO setting were checked for deficiency of glucose-6-phosphate dehydrogenase (G6PD) if there was evidence of hemolysis in the peripheral smear. A final assessment was done after obtaining all the clinical and laboratory information for identifying the possible cause of jaundice.

All the babies were followed up till discharge from the hospital. All phototherapy units were of the same quality and adjusted similarly for distance and wavelength (Lullaby [GE], Zeal medical; 420–470 nm wavelength). Management of pathological hyperbilirubinemia or diagnosis of acute bilirubin encephalopathy was based on the American Academy of Pediatrics guidelines [4]. The outcome was mentioned at the time of discharge as good and poor based on the presence of residual neurological deficit at discharge. Statistical analysis was performed in Statistical Packages for Social Science version 11 (SPSS Inc; Chicago, IL, USA). Predictors for the poor outcome were assessed by the Pearson’s chi-square test, Fisher Exact test, and Student’s t-test. The data were presented as number of patients, percentage, mean, and standard deviation.

**RESULTS**

During the study period, 150 newborns with hyperbilirubinemia had fulfilled the inclusion criteria. There was no missing data. Maternal age (mean ± SD) was 24.9 ± 3.4 years. Most mothers were primigravida, Hindu by religion, and from the hilly region. Nearly four-fifth (79.3%) of babies were born through spontaneous vaginal delivery, followed by cesarean section (12%) and assisted vaginal delivery (8.7%). More than two-third (68%) of the newborns were term and the majority (66%) presented to the hospital at 4th to 7th day of life (Table 1).

The hemoglobin level (mean ± SD) of the newborns was 14.69 ± 2.28 gm/dl. The total serum bilirubin level (mean ± SD) at presentation was 21.73 ± 5.15 mg/dl and the majority (44.7%) had bilirubin level < 20 mg/dl (Table 2). Fifty-five babies (37%) had ABO blood group mismatch with their respective mothers whereas 11 (7.3%) had Rh setting. In 6 (4%) babies, peripheral smear was suggestive of hemolysis without ABO/ Rh setting. Sepsis was found in 52 (34.6%) babies. The remaining 26 (17.4%) babies had no identifiable cause of jaundice.

More than two-third (72%) received only phototherapy and the majority (50%) received it for 24 to 48 h. The duration of phototherapy (mean ± SD) was 47.34 ± 16.68 h. Six babies who had incompatibility suggestive of hemolysis received all forms of therapy including phototherapy, exchange transfusion, and IV immunoglobulin as their total bilirubin level was above the ex-
change range at the time of presentation. The majority (84.5%) had good outcome with complete recovery at discharge. Twenty-three babies had poor outcome with residual neurological deficit at discharge suggestive of acute bilirubin encephalopathy (Table 3).

Among the attributable risk factors assessed, ABO setting, hemolysis, out born babies, total serum bilirubin (TSB) level above 20 mg/dl at presentation and the duration of phototherapy more than 44.8 h predicted poor outcome (Table 4, 5).

### DISCUSSION

This study describes the demographic characteristics of both mothers and new-borns with hyperbilirubinemia, clinical findings at admission, biochemical parameters, risk factors associated with neonatal hyperbilirubinemia, duration of phototherapy, and immediate outcome.

ABO setting was noted in 36.7% of babies whereas Rh setting was noted in 7.3% of the babies. ABO setting has been reported as the most common cause accounting for 13.5% to 27% of the babies with hyperbilirubinemia [1, 7, 8]. None of our babies were found to
have G6PD deficiency. In our study we could not find any cause of neonatal hyperbilirubinemia in 17.3% of babies. Similarly, causes of hyperbilirubinemia were unidentified in one-third of the patients in a study in India [1]. The most likely causes for this group with yet unknown etiology could be breastfeeding jaundice, breast milk jaundice or due to genetic variability [7, 9]. Breastfeeding jaundice developed in 10 to 15% of exclusively breastfed infants during the first week of life [9]. Inadequate feeding may add to dehydration which may significantly increase serum bilirubin levels. A study revealed that inadequate breastfeeding may contribute up to 50% of pathological jaundice [2]. Several studies have revealed that bilirubin, in inadequately breastfed babies, is elevated like an increase in serum bilirubin seen with partial starvation in adults [9, 10].

The average time for presentation in our study was 110.2 ± 58.6 h which also falls within the time of appearance of breastfeeding jaundice. Our babies’ average time for the presentation was a bit longer than 60 hours reported in another study [7]. This may be due to the transportation constraints and hilly geographic location in our country. The mean total bilirubin level at presentation was 21.7 mg/dl in our patients. Studies have reported serum bilirubin before starting phototherapy in the range of 16 to 22 mg/dl [7-10]. Our newborns had bilirubin level on the higher side which may be because of the delayed presentation.

In our study, 72% of the babies required only phototherapy. Twenty-eight percent babies who had total bilirubin levels at or above the exchange range at the time of presentation received both exchange transfusion and phototherapy [4]. Similar proportion of babies requiring different modalities of management as ours has been reported earlier [7]. In contrast, other studies have shown that exchange transfusion was required by fewer babies than ours [10-14]. We had higher rates of exchange transfusion perhaps due to delayed presentation and high value of total serum bilirubin (> 25 mg/dl) at presentation. The duration of phototherapy in our babies was 47 hours. The duration of phototherapy has been variably reported in the range of 24 to 50 hours [7, 12-15].

More than four-fifths of our babies had good outcome without any residual neurological deficit at discharge and around 15% were diagnosed as acute bilirubin encephalopathy at discharge. Many investigators have followed up the newborns up to 1 to 3 months and found that the majority had no neurological impairments [7, 9, 11, 15]. In our study, nearly 19% of the ba-

<table>
<thead>
<tr>
<th>Risk factors</th>
<th>Good outcome (n=127)</th>
<th>Poor outcome (n=23)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prematurity</td>
<td>34/ 93</td>
<td>4/ 19</td>
<td>0.31*</td>
</tr>
<tr>
<td>Septicemia</td>
<td>42/ 85</td>
<td>12/ 11</td>
<td>0.54**</td>
</tr>
<tr>
<td>ABO setting</td>
<td>43/ 84</td>
<td>12/ 11</td>
<td>0.03**</td>
</tr>
<tr>
<td>Rh setting</td>
<td>9/ 118</td>
<td>2/ 21</td>
<td>0.35*</td>
</tr>
<tr>
<td>G6PD deficiency</td>
<td>0/ 127</td>
<td>1/ 22</td>
<td>0.15*</td>
</tr>
<tr>
<td>Place of delivery</td>
<td>Inborn / out born</td>
<td>7/ 16</td>
<td>0.01*</td>
</tr>
<tr>
<td>Hemolysis</td>
<td>1/ 126</td>
<td>5/ 18</td>
<td>&lt; 0.001</td>
</tr>
</tbody>
</table>

*Fisher Exact test, #Pearson's Chi-Square test. G6PD: Glucose-6-phosphate dehydrogenase.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Good outcome (n = 127)</th>
<th>Poor outcome (n = 23)</th>
<th>p-value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maternal age (y)</td>
<td>24.85 ± 3.41</td>
<td>25.22 ± 3.64</td>
<td>0.65</td>
</tr>
<tr>
<td>Birth weight (kg)</td>
<td>2.52 ± 0.65</td>
<td>2.63 ± 0.54</td>
<td>0.42</td>
</tr>
<tr>
<td>HOL</td>
<td>108.010 ± 57.53</td>
<td>122.52 ± 64.28</td>
<td>0.32</td>
</tr>
<tr>
<td>Hb (gm/dl)</td>
<td>14.83 ± 2.28</td>
<td>13.94 ± 2.17</td>
<td>0.08</td>
</tr>
<tr>
<td>TLC (count/mm3)</td>
<td>16943.39 ± 7974.98</td>
<td>17744.34 ± 10116.36</td>
<td>0.82</td>
</tr>
<tr>
<td>TSB (mg/dl)</td>
<td>20.18 ±3.56</td>
<td>30.23 ± 4.22</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Phototherapy duration (h)</td>
<td>44.87 ± 15.95</td>
<td>61.05 ± 14.05</td>
<td>&lt; 0.001</td>
</tr>
</tbody>
</table>

*Student’s t-test. HOL: Hours of life, Hb: Hemoglobin, TLC: Total leukocyte count, TSB: Total serum bilirubin
bries had bilirubin level more than 25 mg/dl at presentation which might be the main reason accounting for the need of exchange transfusion and higher rates of acute bilirubin encephalopathy.

In our study, a high bilirubin at presentation, longer duration of phototherapy, ABO setting, hemolysis, and out born babies developed poor outcome. Similarly, the most common risk factor for significant hyperbilirubinemia in Pakistani study was home delivery (60%), followed by prematurity, low birth weight (55%), sepsis (52%), and hemolysis (30%) [16]. In a Canadian study the most common risk factor was ABO incompatibility in 52%, followed by G6PD deficiency in 21%, other antibody incompatibilities in 12%, hereditary spherocytosis in 7%, urinary tract infection in 2%, and sepsis, pyruvate kinase deficiency, hypothyroidism, or unstable hemoglobin comprising of about 4% [17].

Approximately 15% of our babies with hyperbilirubinemia had an acute bilirubin encephalopathy. Similarly, about 14% of the neonates with severe hyperbilirubinemia had a neurological deficit at discharge in a Canadian study [17]. In a Nigerian study 9.7% of the overall subjects developed kernicterus [18]. In a study of Bangladesh, about 5% of the neonates had a bad neurological outcome including 2% neonatal deaths [19]. In Kanti children hospital, the mortality rate was about 6%, which is way higher than ours and that reported in the literature [20]. Our findings may not reflect the national figure of neonatal hyperbilirubinemia and its outcome as this study was conducted in the tertiary care center of eastern Nepal where most of the babies with pathological hyperbilirubinemia are referred from other hospitals for exchange transfusion as it is the only place where exchange transfusion is performed till this study was concluded.

The neonates who had poor outcome had neurological deficit at discharge. Those babies were mostly out born/ home delivered and had significant hyperbilirubinemia (20 mg/dl) at presentation. They had presented with features of acute bilirubin encephalopathy with increased tone and decreased activity and most had hung up Moro’s at admission. Most of the babies with poor outcome had ABO settings. Those babies who had peripheral smear suggestive of hemolysis had significant hyperbilirubinemia and almost all of them received exchange therapy and IV Immunoglobulin in addition to phototherapy and the duration of phototherapy was also longer in the babies with poor neurological outcome than those who had good outcome.

This study mainly reflects the outcome in eastern part of Nepal which may not imply to other parts of the country. If more similar studies are conducted at other centres in different parts of Nepal, the results may be generalized.

**CONCLUSION**

In this study, about 15% of the babies with hyperbilirubinemia had acute bilirubin encephalopathy at discharge suggestive of poor outcome. Babies with high bilirubin at presentation, longer duration of phototherapy, ABO settings, hemolysis, and out born status developed poor outcome. With still a high rates of invasive exchange transfusion accounting 32% at our centre, we recommend that proper information regarding neonatal jaundice should be provided to all mothers before discharge so that they may report back timely. This may help decrease the incidence of acute bilirubin encephalopathy in the newborns.

**References**

10. Gartner U, Goeser T, Volkkoff AV. Effect of fasting on the uptake


